Publication: Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells
Issued Date
2020-12-01
Resource Type
ISSN
18781705
15675769
15675769
Other identifier(s)
2-s2.0-85097147853
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Immunopharmacology. Vol.89, (2020)
Suggested Citation
Thanich Sangsuwannukul, Kamonlapat Supimon, Jatuporn Sujjitjoon, Nattaporn Phanthaphol, Thaweesak Chieochansin, Naravat Poungvarin, Sopit Wongkham, Mutita Junking, Pa thai Yenchitsomanus Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells. International Immunopharmacology. Vol.89, (2020). doi:10.1016/j.intimp.2020.107069 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/60488
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells
Other Contributor(s)
Abstract
© 2020 Elsevier B.V. Current treatment of cholangiocarcinoma (CCA) – a lethal bile duct cancer – is ineffective because the disease is usually diagnosed at late and advanced stage. Thus, a novel therapeutic modality is urgently required. Fourth-generation chimeric antigen receptor (CAR4) T cells was created to target CD133, a well-known cancer stem cell marker, that is highly expressed and associates with cancer progression. The anti-CD133-CAR4 T cells showed high efficacy against CD133-expressing CCA cells. Tumour cell lysis occurred in a dose- and CD133 antigen-dependent manner, and significantly higher, up to 57.59% ± 9.62 at effector to target ratio of 5:1 in a CCA cell line – KKU-213A cells, compared to mock control (p = 0.008). Similarly, significant IFN-γ (p = 0.011) and TNF-α (p = 0.002) upregulation was observed upon tumour treatment. The effectiveness of our anti-CD133-CAR4 T cells will be beneficial not only for CD133-expressing CCA, but also for other CD133-expressing tumours. This study may guide future in vivo study and clinical trials.